- Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment2021 | First Faculty of Medicine
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial2022 | First Faculty of Medicine
- The use of niraparib in the treatment of ovarian cancer2023 | First Faculty of Medicine
- Platinum-sensitive recurrent ovarian cancer and olaparib maintenance treatment - case report2019 | First Faculty of Medicine
- PARP inhibitors in treating metastatic castration-resistant prostate cancer2023 | First Faculty of Medicine
- Treatment strategy of triple negative breast cancer in young women - do we treat them differently?2023 | First Faculty of Medicine
- Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)2021 | Publication without faculty affiliation
- WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors2019 | Central Library of Charles University
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Genetic testing in ovarian cancer2022 | First Faculty of Medicine
- Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment2020 | Publication without faculty affiliation
- European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerPublication without faculty affiliation